APLS Quote, Financials, Valuation and Earnings

Macrogenics has a net margin of -17.11% compared to Apellis Pharmaceuticals's net margin of -86.98%. Apellis Pharmaceuticals's return on equity of -83.06% beat Macrogenics's return on equity of -60.58%.

Apellis Pharmaceuticals has a consensus price target of $41.53, signalling upside risk potential of 137.43%. On the other hand Macrogenics has an analysts' consensus of $5.80 which suggests that it could grow by 239.18%. Given that Macrogenics has higher upside potential than Apellis Pharmaceuticals, analysts believe Macrogenics is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.850, which suggesting that the stock is 14.967% less volatile than S&P 500. In comparison Macrogenics has a beta of 2.234, suggesting its more volatile than the S&P 500 by 123.417%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $212.5M, which are larger than Macrogenics quarterly revenues of $17.7M. Apellis Pharmaceuticals's net income of -$36.4M is lower than Macrogenics's net income of -$15.4M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.77x versus 0.72x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -17.11% compared to Apellis Pharmaceuticals's net margin of -3965.99%. Apellis Pharmaceuticals's return on equity of -83.06% beat Recursion Pharmaceuticals's return on equity of -77.06%.

Apellis Pharmaceuticals has a consensus price target of $41.53, signalling upside risk potential of 137.43%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $8.71 which suggests that it could grow by 52.08%. Given that Apellis Pharmaceuticals has higher upside potential than Recursion Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Recursion Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.850, which suggesting that the stock is 14.967% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $212.5M, which are larger than Recursion Pharmaceuticals quarterly revenues of $4.5M. Apellis Pharmaceuticals's net income of -$36.4M is higher than Recursion Pharmaceuticals's net income of -$178.9M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.77x versus 26.88x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Y-mAbs Therapeutics has a net margin of -17.11% compared to Apellis Pharmaceuticals's net margin of -25.63%. Apellis Pharmaceuticals's return on equity of -83.06% beat Y-mAbs Therapeutics's return on equity of -30.91%.

Apellis Pharmaceuticals has a consensus price target of $41.53, signalling upside risk potential of 137.43%. On the other hand Y-mAbs Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 292.68%. Given that Y-mAbs Therapeutics has higher upside potential than Apellis Pharmaceuticals, analysts believe Y-mAbs Therapeutics is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.850, which suggesting that the stock is 14.967% less volatile than S&P 500. In comparison Y-mAbs Therapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.931%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Y-mAbs Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Y-mAbs Therapeutics pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $212.5M, which are larger than Y-mAbs Therapeutics quarterly revenues of $26.5M. Apellis Pharmaceuticals's net income of -$36.4M is lower than Y-mAbs Therapeutics's net income of -$6.8M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Y-mAbs Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.77x versus 2.07x for Y-mAbs Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.